AACR: Higher melatonin levels tied to lower prostate cancer risk

AACR: Higher Melatonin Linked to Lower Prostate Cancer Risk
AACR: Higher Melatonin Linked to Lower Prostate Cancer Risk

(HealthDay News) -- Men with higher levels of melatonin may have a lower risk of developing prostate cancer, according to a study presented at the AACR-Prostate Cancer Foundation Conference on Advances in Prostate Cancer Research, held from Jan. 18 to 21 in San Diego.

Sarah C. Markt, M.P.H., from the Harvard School of Public Health in Boston, and colleagues examined the association between urinary 6-sulfatoxymelatonin concentrations, sleep patterns, and the risk of prostate cancer in 928 Icelandic men from 2002 to 2009.

The researchers found that 111 men were newly diagnosed with prostate cancer, including 24 with advanced disease. The median concentration of 6-sulfatoxymelatonin was 17.14 nanograms per milliliter. Levels of 6-sulfatoxymelatonin were significantly lower in men who reported sleep problems at baseline. After adjusting for potential confounders, men with high levels of 6-sulfatoxymelatonin had a significantly lower prostate cancer risk (hazard ratio, 0.25).

"Higher urinary 6-sulfatoxymelatonin levels were associated with a decreased risk of prostate cancer, particularly advanced disease," Markt and colleagues conclude.

Press Release
More Information

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs